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Abstract
Natural killer (NK) cells are innate immune lymphocytes that 
play an important role in anti-viral and anti-tumour immune 
responses. Several cancer immunotherapy approaches tar-
geting NK cells are currently in clinical or preclinical develop-
ment. Here, we aimed to find food nutrients that activate NK 
cells and determine their usefulness as candidates for anti-
cancer and anti-metastatic drugs. Resveratrol appeared to 
activate NK cells most effectively among the substances test-
ed and synergistically increased IFN-γ secretion and NK cell 
cytotoxicity with interleukin-2 (IL-2). CD107a, NKp30, and 
NKG2D expression levels were upregulated on the surface of 
NK cells upon treatment with resveratrol in combination 
with IL-2 compared with treatment with IL-2 alone. More-
over, NK cell activity in human and mouse whole blood was 
enhanced upon treatment with resveratrol. Most important-
ly, administration of resveratrol effectively inhibited tumour 
growth and metastasis in mice. In conclusion, we suggest 
that resveratrol may represent a candidate anti-cancer drug 
that acts by activating NK cells in vivo.
© 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Natural killer (NK) cells are innate immune lympho-
cytes accounting for about 15% of all circulating lympho-
cytes that spontaneously kill cells deemed to be danger-
ous to the host in the absence of prior sensitization; they 
thus are presumed to be key effectors in cancer immuno-
surveillance, transplantation rejection, and early viral im-
munity [1–3]. Recently, it was reported that physical ac-
tivity and metabolic status may alter the immune system 
and that physical inactivity and metabolic abnormalities 
are associated with reduced NK cell activity [4]. Further, 
NK cells are potent killers of malignant cells and are par-
ticularly important in limiting tumour metastasis [5, 6]. 
NK cells can inhibit tumour growth by direct cytotoxicity 
through the release of cytolytic granules, by secretion of 
cytokines such as interferon-gamma (IFN-γ), or indirect-
ly by the orchestration of anti-tumour immune responses 
[7]. NK cells are activated by Th1-type cytokines, such as 
interleukin (IL)-2, -12, -15, or -18, natural cytotoxicity 
receptors, and NKG2D [8–10]. When NK cells are acti-
vated, they secrete large amounts of IFN-γ, which is es-
sential in viral and tumour clearance and activates the 
signal transducers and activators of transcription (STAT) 
signalling pathway in target cells, leading to the improved 
control of infection [11, 12]. IFN-γ production by NK 
cells restricts tumour angiogenesis, stimulates adaptive 
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immunity, and helps shape T-cell responses in lymph 
nodes [13].
Third-generation immunotherapy represents a new 
paradigm for cancer treatment [14]. As the focus of treat-
ment has shifted from the tumour itself to the host’s im-
mune system, cancer immunotherapies activating the 
body’s immune system to fight cancer cells have been de-
veloped. Most immunotherapeutic strategies focus on 
enhancing T-cell responses; however, there has been re-
cent interest in using the relatively underexplored NK cell 
compartment for therapeutic interventions [15–17]. 
Moreover, it is becoming clear that some of the clinical 
approaches originally developed to increase T-cell cyto-
toxicity may also activate NK cells [16].
In some clinical studies, the use of a low dose of IL-2, 
alone or in combination with other agents (such as low-
dose IL-2 and IFN-α), results in similar clinical response 
rates and survival probabilities as the use of high doses of 
IL-2 alone [18]. Unfortunately, cytokines and other small 
molecules secreted by IL-2-activated effector cells induce 
toxicity, which offsets the efficacy of IL-2. To overcome 
this limitation, studies of therapies involving new cyto-
kines are underway, including the use of IL-12 alone or in 
combination with IL-2 [19, 20]. In the last decade, the 
field of nutritional immunology has grown steadily. We 
hypothesized that, in addition to cytokines, there may be 
substances among natural compounds with the ability to 
activate NK cells [21].
Here, we screened several compounds including anti-
oxidants, vitamins, and food ingredients to identify com-
pounds that can activate NK cells. Furthermore, we dem-
onstrated the potential of one of these compounds, resve-
ratrol, as an anti-cancer and anti-metastatic drug 
candidate, which may act via NK cell activation. Overall, 
our finding enlightens the novel function of resveratrol as 
an NK booster, which can be the potential adjuvant for 
immunotherapeutics in cancers.
Materials and Methods
Cell Lines and Cell Culture
The human NK cell line NK92 (ATCC® CRL-2407TM) was 
maintained in the minimum essential medium-α (MEM-α) (Gibco, 
New York, NY, USA) supplemented with 12.5% heat-inactivated 
foetal bovine serum (FBS; Gibco), 12.5% heat-inactivated horse se-
rum (Gibco), 0.2-mM myo-inositol (Sigma-Aldrich, St. Louis, MO, 
USA), 0.1-mM 2-mercaptoethanol (Sigma-Aldrich), 0.02-mM folic 
acid (Sigma-Aldrich), 1% penicillin/streptomycin (WelGENE, 
Gyeongsansi, Korea), and 5 ng/mL IL-2 (ATGen, Sungnamsi, Ko-
rea). Human erythroleukemia cell line K562 (ATCC® CCL-243TM) 
was maintained in the RPMI 1640 medium (Gibco) supplemented 
with 10% FBS and 1% penicillin/streptomycin. Mouse melanoma 
cell line B16F10 (ATCC® CRL-6475TM) was maintained in Dulbec-
co’s modified Eagle’s medium (DMEM) (Gibco) supplemented 
with 10% FBS and 1% penicillin/streptomycin.
Antibodies and Reagents
Resveratrol, 3-amino-1-propanesulfonic acid (3-APS), gluta-
thione, taurine, glycine, alanine, β-alanine, β-carotene, retinoic 
acid, retinol, retinal, tazarotene, vitamin B1, vitamin B12, vitamin 
D3, 2,3-butandiol, quercetin, triacetyl resveratrol, and piceatannol 
were purchased from Sigma-Aldrich. Lycopene and catechin were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
Resveratrol-3-O-glucuronide was purchased from Cayman Chem-
ical (Ann Arbor, MI, USA). Resveratrol-4′-glucuronide was pur-
chased from Spibio (Montigny Le Bretonneux, France). Resvera-
trol-trisulphate was purchased from Carbosynth (Berkshire, UK). 
For flow cytometry, PE-conjugated anti-human CD107a antibody 
(555801) and APC-conjugated anti-human CD56 antibody 
(555518) were purchased from BD Pharmingen (San Diego, CA, 
USA). BV421-conjugated anti-human CD3 antibody (300434), 
APC-Cy7-conjugated anti-human CD16 antibody (302017), PE-
conjugated anti-human NKG2D antibody (320806), PE-conjugat-
ed anti-human NKp30 antibody (325208), PE-conjugated anti-hu-
man NKp44 antibody (325108), PE-conjugated anti-human 
NKp46 antibody (331908), BV650-conjugated anti-mouse TCRβ 
antibody (109251), PE-conjugated anti-mouse NK1.1 antibody 
(108708), PerCP-Cy5.5-conjugated anti-mouse IFN-γ antibody 
(505822), and PE-Cy7-conjugated anti-mouse CD107a antibody 
(121619) were purchased from BioLegend (San Diego, CA, USA).
Cell Proliferation Assay
Cell proliferation was measured using the CCK-8 assay kit 
(Dojindo Laboratories, Kumamoto, Japan). NK92 cells (1 × 104 
cells/well) (100 μL) were dispensed in triplicate into a 96-well flat-
bottom plate and incubated for 4 h. After incubation, 10 μL of the 
CCK-8 solution was added to each well. After 4 h, absorbance was 
measured at 450 nm using a microplate reader.
ELISA
An IFN-γ ELISA set was purchased from BD Biosciences (San 
Diego, CA, USA). NK92 cells (5 × 104 cells/well) were dispensed 
into a 24-well plate and incubated for 36 h. Then, the supernatants 
were harvested and dispensed in triplicate into a 96-well microplate 
pre-coated with capture antibody. After incubation for 2 h, each 
well was washed with the washing buffer (0.05% Tween 20 in PBS, 
pH 7.4), followed by the addition of HRP-conjugated detection an-
tibody and incubation for 1 h. The substrate solution 3,3′,5,5′-tet-
ramethylbenzidine (TMB) was added under protection from light. 
Absorbance was measured at 450 nm using a microplate reader.
CD107a Degranulation Assay
NK92 cells were treated with or without resveratrol and incu-
bated for 36 h. After incubation, NK92 cells (2 × 104 cells/well) 
were dispensed into a 96-well round-bottom plate and incubated 
with an equal number of K562 target cells. Then, anti-CD107a an-
tibody was added, and the plate was incubated for 4 h. Cells were 
harvested and stained with anti-CD56 antibody for 30 min on ice. 
After 2–3 washes with PBS containing 1% FBS, fluorescence was 
measured using a BD LSR II flow cytometer (BD Biosciences). 
PBMCs were treated with or without resveratrol for 24 h in the 
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presence of IL-2. After incubation, PBMCs were incubated with 
K562 cells (5:1 ratio) for 4 h. Cells were harvested and stained with 
anti-CD3, -CD16, and -CD56 antibody in the presence of fixable 
live/dead stain (Invitrogen) for 30 min on ice. After 2–3 washes 
with PBS containing 1% FBS, fluorescence was measured using a 
BD LSR II flow cytometer (BD Biosciences).
Flow Cytometry
NK92 cells (5 × 104 cells/500 μL) were incubated with or with-
out resveratrol. After incubation, cells were washed twice with PBS 
containing 1% FBS and stained with fluorochrome-conjugated an-
tibodies in PBS containing 1% FBS for 30 min on ice in the dark. 
The cells were washed twice, and then fluorescence was measured 
using BD LSR II.
Real-Time PCR Analysis
Total RNA was extracted from NK92 cells using TRIzol (Life 
Technologies, Carlsbad, CA, USA), and cDNA was synthesized 
using the SensiFAST cDNA synthesis kit (Bioline, Taunton, MA, 
USA) according to the manufacturer’s instructions. Synthesized 
cDNAs were used as templates for subsequent PCR amplification 
of the IFNG, NKp30 isoforms, and GAPDH genes. The following 
primers were used:
1. IFNG, 5′-GTCCAACGCAAAGCAATACA-3′ and 5′-CTCT-
TCGACCTCGAAACAGC-3′
2. NKp30a, 5′-GGTGGTGGAGAAAGAACATC-3′ and 5′-CTT-
TCCAGGTCAGACATTTGC-3′
3. NKp30b, 5′-GGTGGTGGAGAAAGAACATC-3′ and 5′-GAG-
AGTAGATTTGGCATATTTGC-3′
4. NKp30c, 5′-GGTGGTGGAGAAAGAACATC-3′ and 5′-CAT-
GTGACAGTGGCATTTGC-3′
5. GAPDH, 5′-CAGCCTCAAGATCATCAGCA-3′ and 5′-GTC-
TTCTGGGTGGCAGTGAT-3′
Quantitative real-time RT-PCR was carried out using a KAPA 
SYBR FAST qPCR kit (KAPA Biosystems, Wilmington, MA, USA), 
and amplification was performed on an ABI Prism StepOnePlusTM 
detection system (Applied Biosystems, Foster City, CA, USA) ac-
cording to the conditions recommended by the manufacturer. The 
experiments were performed in triplicate, and results were normal-
ized to the expression of GAPDH. The relative expression levels of 
the target genes were calculated by the 2−ΔΔCt method.
Cytotoxicity Assay
The calcein-AM (Invitrogen, Carlsbad, CA, USA) assay was 
used to measure NK cell cytotoxicity against target cells. Calcein-
AM was added to target cells to a final concentration of 2 μM and 
incubated for 30 min at 37°C and 5% CO2. Calcein-AM-labelled 
target cells were washed with PBS twice, and then 1 × 104 cells were 
dispensed in quadruplicate into a 96-well round-bottom plate. NK 
cells were added at different effector:target (E:T) ratios and co-
cultured for 4 h. The calcein-AM released from lysed target cells 
was measured with a spectrophotometer (ex: 485 nm/em: 535 nm). 
Total specific lysis was calculated by the following formula:




experimental release spontaneous release
Specific cytotoxicity % 100
maximum release spontaneous release
 
Ex vivo NK Cell Activity Assay
Blood was obtained from healthy donors after acquiring insti-
tutional review board approval and informed consent (No. 4-2019-
0007). Animal experiments were approved by the Yonsei Univer-
sity Health System Institutional Animal Care and Use Committee 
(YUHS-IACUC, No. 2017-0203).
For the human NK cell activity assay, 1 mL of whole blood was 
incubated with the activator (provided as part of the kit) for 24 h 
at 37°C under 5% CO2 (n = 13). For the analysis of mouse NK cell 
activity, 100 μL of whole blood was incubated with 30 μL activator 
for 24 h at 37°C (tumour-naïve or tumour-bearing mouse model, 
n = 8). After incubation, the supernatant was collected, and the 
released IFN-γ was measured using the murine NK Vue kit (AT-
Gen). Standards and samples were then incubated in an anti-hu-
man (or murine) IFN-γ antibody-coated plate for 2 h (1 h for mu-
rine) at 20–25°C. After incubation, each well was washed 4 times 
before the addition of HRP-conjugated detection antibody and in-
cubated for 1 h. Each well was washed 7 times (4 times for murine), 
and then the TMB substrate solution was added in the dark. After 
incubation for 30 min, the stop solution was added, and absor-
bance was measured at 450 nm.
Animal Studies
Animal experiments were approved by the Yonsei University 
Health System Institutional Animal Care and Use Committee 
(YUHS-IACUC, No. 2017-0203). Specific pathogen-free female 
C57BL/6 mice, 7 weeks of age, were purchased from Orient Bio 
(Seoul, Korea). Mice were maintained in a temperature-controlled, 
air-conditioned animal house under a 12/12-h light/dark cycle and 
received food and water ad libitum. Animals were cared for and treat-
ed in accordance with the procedures outlined in the Guide for the 
Care and Use of Laboratory Animals (National Research Council, 
WA, DC, USA). B16F10 cells were used between passages 4 and 5.
For the anti-tumour assay, B16F10 cells (5 × 105 cells) in 0.2 mL 
of PBS were injected subcutaneously (s.c.) into the right flanks of 
mice on day 0. On day 18, the mice were sacrificed, and the tumours 
were dissected. The activity of NK cells isolated from the tumour and 
draining lymph nodes was evaluated by flow cytometry. Tumour vol-
ume was calculated for each mouse by measuring the length (L), 
width (W), and height/diameter (H) of approximately ellipsoid tu-
mours using a caliper, according to the following formula:
Tumor volume (mm3) = L × W × H × 0.52
For the pulmonary tumour metastasis assay, B16F10 cells at a 
concentration of 1 × 105 cells in 0.1 mL of PBS were injected intra-
venously (i.v.) into the tail veins of mice on day 0. On day 18, the 
mice were sacrificed, and the lungs were extracted. The melanoma 
foci on the lung surface were counted macroscopically. The activity 
of NK cells isolated from the lungs was evaluated by flow cytometry.
To evaluate the activity of resveratrol, 0.5 mg/kg of resveratrol 
in 0.1 mL of PBS was i.v. injected a total of 6 times, on days −2, 0, 
2, 4, 6, and 8 (n = 10 or 7).
NK Cell Depletion Model
To deplete NK cells, 25 μg anti-NK1.1 monoclonal antibody 
(PK136) or control mouse IgG2a (both from Bio-X-Cell) was inject-
ed intraperitoneally (i.p.) on days −3, 2, and 8. B16F10 cells (5 × 105 
cells) in 0.2 mL of PBS were injected subcutaneously into the right 
flanks of mice on day 0. On day 18, the mice were sacrificed, and the 
tumours were dissected, and tumour volume was calculated.
Statistical Analysis
Statistical analysis was performed with GraphPad Prism soft-
ware (GraphPad Software, San Diego, CA, USA). Data are ex-
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pressed as means ± standard error of the mean (SEM). One- or 
two-way ANOVA was used to compare distributions between 
groups. p < 0.05 was considered statistically significant.
Results
Screening of NK Cell-Activating Molecules
To identify a non-cytokine natural substance capable of 
activating NK cells, several compounds, including known 
antioxidants (Fig. 1a), vitamin-based substances (Fig. 1b), 
and food ingredients (Fig. 1c), were tested for their ability 
to activate NK92 cells. In this study, the vehicle is the sol-
vent control which contains the same amount of ethanol 
used to dissolve each compound. Since NK cells require 
IL-2 to proliferate, the experiment was conducted in the 
presence of IL-2. Most of the compounds appeared to have 
no effect on NK cell viability when added at a concentra-
tion of up to 20 μM, whereas retinoic acid and retinal slight-
ly inhibited cell proliferation (data not shown). IFN-γ se-
cretion was next measured to determine whether NK cells 
were activated by these substances. Interestingly, while 
most substances appeared to have no effect on IFN-γ secre-
tion, only resveratrol significantly increased IL-2-induced 
IFN-γ secretion about 2-fold compared to that of IL-2 
treatment alone, suggesting potential roles of resveratrol in 
activating NK cells (Fig. 1).
Resveratrol Increased IL-2-Induced IFN-γ Secretion 
from NK Cells
As mentioned above, among the antioxidants, vita-
mins, and food nutrients tested, only resveratrol appeared 
to increase the IFN-γ secretion from NK cells (Fig.  1). 
Moreover, as shown in Figure 2a, b, resveratrol did not 
significantly affect NK cell proliferation but increased 
IFN-γ secretion in a dose-dependent manner. Particular-
ly, at a resveratrol concentration of 20 μM, IFN-γ secre-
tion was increased by >50% compared to that of IL-
2-alone-treated cells (Fig. 2b). Next, we measured NK cell 
proliferation and IFN-γ secretion after treatment with 
resveratrol with or without IL-2 to investigate whether 
resveratrol is effective as a replacement for IL-2 or has 
synergistic effects in combination with IL-2. As shown in 
Figure 2c, d, resveratrol had no effect in the absence of 
IL-2. Moreover, in the presence of IL-2, NK cell prolif-
eration was not affected by resveratrol (Fig.  2c). While 
IFN-γ secretion was not altered for up to 12 h after treat-
ment, it thereafter increased by about 40% or more com-
pared to that observed in the group treated with IL-2 
alone (Fig. 2d). We also confirmed by real-time PCR that 
the mRNA level of IFNG was upregulated by resveratrol 
treatment in the presence, but not the absence, of IL-2 
(Fig. 2e). Altogether, these results indicate that resvera-
































































































































































Fig. 1. Screening of NK cell-activating molecules. a–c Comparisons of IFN-γ secretion in NK92 cells treated with 
resveratrol and other compounds (with 5 ng/mL of IL-2) for 36 h. IFN-γ secretion was measured by ELISA. Data 
are shown as mean ± SEM of 4 independent experiments. Asterisks indicate statistical significance by one-way 
ANOVA: *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant (p > 0.05). IL-2, interleukin-2; IFN-γ, interferon-
gamma.
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Effects of Resveratrol on NK Cell Activity and 
Activating Receptor Expression
We next examined the effects of resveratrol on NK cell 
degranulation activity by measuring CD107a expression 
as a functional marker of NK cell activation [22]. NK cells 
were co-incubated with K562 target cells, which do not 
express major histocompatibility complex (MHC) class I 
molecules and are susceptible to NK cell-mediated killing 
[23]. This was followed by analysis of surface levels of 
CD107a by flow cytometry. As shown in Figure 3a, after 
NK cells were pretreated with IL-2, NK cells expressing 
CD107a accounted for 18.3 ± 0.23% of all CD56+ NK 
cells. CD107a expression on the surface of NK cells pre-
treated with resveratrol and IL-2 increased 1.8-fold com-
pared to that on the surface of IL-2-alone-pretreated cells, 
resulting in 32.9 ± 2.59% of CD56+ NK cells expressing 
CD107a. Next, we measured the effects of resveratrol on 
the expression of NK cell-activating receptors which have 
central roles for NK cell cytotoxicity. As shown in Figure 
3b, the expression of NK cell-activating receptors was sig-
nificantly increased by resveratrol more than IL-2 alone. 
Since a previous study has shown immunomodulatory 
functions of NKp30 depending on its isoforms [24], we 
analyzed the change in the expression level of NKp30 iso-
forms upon IL-2 with or without resveratrol treatment. 
While resveratrol did not affect the expression of NK-
p30c, known as an inhibitory Nkp30 isoform [24], the 
activating isoforms including NKp30a as well as NKp30b 
were significantly increased by resveratrol (Fig. 3c). Alto-
gether, these results suggest that resveratrol might en-
hance overall cytotoxicity of NK cells. Hence, we exam-
ined the effect of resveratrol on the cytotoxicity of NK 
cells. Consistent with previous studies, IL-2 treatment 
significantly enhanced the killing activity of NK cells 
(Fig. 3d). Intriguingly, co-treatment of resveratrol togeth-
er with IL-2 further heightened NK cytotoxicity by 21.3% 
compared with IL-2-treated cells at 1:1 ratio, indicating 
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Fig. 2. Resveratrol increased IL-2-induced IFN-γ secretion from 
NK cells. a, b NK92 cells were treated with 0–20 μM resveratrol 
in the presence of 5 ng/mL IL-2 for 36 h. c, d NK92 cells were 
treated with 20 μM resveratrol for 0–48 h with or without 5 ng/
mL IL-2. e The mRNA levels of IFNG in NK92 cells after treat-
ment of resveratrol for 24 h were measured by real-time PCR and 
calculated by the ΔΔCT method. Gapdh was used as an internal 
control. Data are shown as mean ± SEM of 3 independent experi-
ments. Asterisks indicate statistical significance by one- or two-
way ANOVA: *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant 
(p > 0.05). RES, resveratrol; IL-2, interleukin-2; IFN-γ, interferon-
gamma.
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Fig. 3. Effects of resveratrol on NK cell activity and activating re-
ceptor expression. a CD107a expression on the surface of NK92 
cells after resveratrol treatment was measured by flow cytometry. 
NK92 cells were treated with 20 μM resveratrol for 36 h, followed 
by co-culture with K562 target cells at a 1:1 ratio for 4 h. Quantita-
tive analysis showing the percentages of CD56+ CD107a+ cells. 
Data are shown as mean ± SEM of 3 independent experiments. 
b Expression of natural cytotoxicity receptors and NKG2D was 
measured by flow cytometry. NK92 cells were treated with 20 μM 
resveratrol for 36 h. Data are shown as mean ± SEM of 3 indepen-
dent experiments. c The mRNA levels of NKp30 isoforms in NK92 
cells after treatment of resveratrol for 6 h were measured by real-
time PCR and calculated by the ΔΔCT method. Gapdh was used as 
an internal control. Data are shown as mean ± SEM of 4 indepen-
dent experiments. d NK cell cytotoxicity was determined using 
calcein-AM. NK92 effector (E) cells were treated with 20 μM res-
veratrol for 36 h, followed by incubation with K562 target (T) cells 
at a 1:1 ratio for 4 h. Data are shown as mean ± SEM of 3 indepen-
dent experiments. Asterisks indicate statistical significance by one-
way ANOVA: *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant 
(p > 0.05). RES, resveratrol; IL-2, interleukin-2; NK cells, natural 
killer cells.
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Effects of Derivatives and Metabolites of Resveratrol
Resveratrol is currently marketed as a dietary supple-
ment. Triacetyl resveratrol, a derivative of resveratrol, is 
easily converted to resveratrol by esterase activity and ex-
hibits similar bioactivity as resveratrol in cell cultures. 
Once resveratrol was absorbed, it is rapidly metabolized 
by conjugation to the hydroxyl group, glucuronic acid, 
and/or sulphate. The sites of glucuronidation in resvera-
trol in the 3- and 4′-positions have been firmly estab-
lished after synthesis of the metabolites. Similarly, the 
major site of sulphate conjugation, in the 4′-position, was 
also established by synthesis (Fig. 4a) [25]. So, we inves-
tigated whether the derivative or any of the metabolites of 
resveratrol could activate NK cells better than resveratrol 
itself. First, we investigated the effects of these com-
pounds on NK cell proliferation. Triacetyl resveratrol, a 
derivative of resveratrol, slightly inhibited cell prolifera-





































































































































































































Fig. 4. Effects of derivatives and metabolites of resveratrol. a Me-
tabolism of resveratrol and structures of resveratrol, triacetyl res-
veratrol (derivative of resveratrol), and metabolites of resveratrol. 
Resveratrol is metabolized by hydroxylation or glucuronidation or 
sulphate conjugation to produce combined forms of sulphate and 
glucuronide. b, c Cell proliferation and IFN-γ secretion in NK92 
cells after indicated treatments at 20 μM (with 5 ng/mL of IL-2) for 
36 h were determined by CCK-8 and ELISA. Data are shown as 
mean ± SEM of 3 independent experiments. d NK cell cytotoxicity 
was determined using calcein-AM. NK92 effector (E) cells were 
treated with 20 μM resveratrol or its metabolites for 36 h, followed 
by incubation with K562 target (T) cells at a 1:1 ratio ratio for 4 h. 
Data are shown as mean ± SEM of 4 independent experiments. 
Asterisks indicate statistical significance by one-way ANOVA: 
*p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant (p > 0.05). 
IL-2, interleukin-2; IFN-γ, interferon-gamma; RES, resveratrol.
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measured IFN-γ secretion in NK cells after treatment 
with the resveratrol derivative and metabolites. As shown 
in Figure 4c, the derivative and most of the metabolites 
did not affect IFN-γ secretion. Triacetyl resveratrol and 
resveratrol trisulphate increased IFN-γ secretion com-
pared to that observed in IL-2-alone-treated cells, but 
their effect was weaker than that of resveratrol. Finally, we 
examined the effects of triacetyl resveratrol and resvera-
trol trisulphate on NK cytotoxicity using K562 target cells 
and the calcein-AM method. As shown in Figure 4d, after 
treatment with resveratrol itself, NK cytotoxicity was in-
creased by 20% at an E:T ratio of 1:1, compared to that of 
IL-2 treatment alone. After triacetyl resveratrol treat-
ment, NK cytotoxicity was increased by 11.4% at an E:T 
ratio of 1:1, but not significant. Unlike resveratrol and 
triacetyl resveratrol, resveratrol trisulphate did not affect 
NK cytotoxicity. These results indicate that the intact 
form of resveratrol is the most effective for activating NK 
cells.
Anti-Cancer and Anti-Metastatic Effects of 
Resveratrol in Mice
We examined the in vivo efficacy of resveratrol ad-
ministration in melanoma mouse models. In vivo activa-
tion of NK cells by resveratrol and its anti-cancer effects 
were assessed by 2 different methods. First, 18 days after 
s.c. injection of B16F10 cells, tumour volumes were mea-
sured after dissection. As shown in Figure 5a, adminis-
tration of resveratrol (0.5 mg/kg) in the presence of IL-2 
significantly inhibited tumour growth compared to the 
administration of IL-2 alone. Quantitative analysis 
showed that administration of IL-2 inhibited tumour 
growth compared to that in vehicle control mice. Fur-
thermore, administration of resveratrol in the presence 
of IL-2 significantly inhibited tumour growth compared 
to the administration of IL-2 alone. Treatment of resve-
ratrol together with IL-2 significantly inhibited tumour 
growth (Fig. 5a) accompanied with robust activation of 
NK cells in the tumour (Fig. 5b) as well as draining lymph 
nodes (Fig. 5c) compared to the vehicle or IL-2-treated 
group.
Second, we investigated whether resveratrol affects 
tumour metastasis in the lung metastatic model as well. 
B16F10 cells were i.v. injected into mice; after 18 days, 
the lungs were extracted, and melanoma foci on lung sur-
faces were counted. As shown in Figure 5d, the number 
of melanoma foci decreased in mice treated with resve-
ratrol. Furthermore, IFN-γ production and degranula-
tion levels were significantly enhanced in the lung resid-
ual NK cells by the treatment of resveratrol compared 
with the vehicle or IL-2-treated group (Fig. 5e). These 
results suggest that resveratrol may prohibit tumour 
growth and metastasis by activating NK cells. Finally, to 
clarify the intrinsic roles of NK cells on anti-tumoural ef-
fects of resveratrol, mice were injected with tumour and 
treated with vehicle, resveratrol, or resveratrol plus anti-
NK1.1 to deplete NK cells in vivo. Intriguingly, as shown 
in Figure 5f, anti-tumoural effects of resveratrol was al-
most completely abrogated by the depletion of NK cells. 
Consistent with previous results, resveratrol treatment 
with isotype antibody significantly reduced tumour 
growth. However, anti-tumoural effects of resveratrol 
were completely abrogated upon the depletion of NK 
cells (Fig. 5f). Altogether, these results indicate the piv-
otal roles of NK cells for resveratrol-dependent anti-tu-
moural effects.
Ex vivo Effects of Resveratrol in Human and Mouse 
Whole Blood
Further, we investigated the effect of resveratrol on hu-
man and mouse NK cell activity in whole blood using the 
NK Vue kit. After resveratrol treatment with the activa-
tor, human NK cell activity increased by about 25% com-
pared to treatment with the activator alone (Fig. 6a). Like-
wise, after resveratrol treatment with the activator, tu-
mour-naïve mouse NK cell activity increased by about 
27.2% compared to treatment with the activator alone 
(Fig. 6b). Also, NK cell activity was measured in tumour-
Fig. 5. Anti-cancer and anti-metastatic effects of resveratrol in 
mice. B16F10 cells (5 × 105) in 0.2 mL PBS were injected subcuta-
neously into C57BL/6 mice on day 0 (n = 14). a The tumour vol-
ume was measured after dissection on day 18 after injection of 
melanoma cells. The activity of NK cells isolated from tumour (b) 
and draining lymph node (c) was evaluated by flow cytometry. 
B16F10 cells (1 × 105) in 0.1 mL PBS were injected into the tail 
veins of C57BL/6 mice on day 0 (n = 10). d The melanoma foci on 
the lung surface were counted macroscopically 18 days after injec-
tion of melanoma cells. e The activity of NK cells isolated from the 
lungs was evaluated by flow cytometry. f To deplete NK cells, 
25 μg anti-NK1.1 monoclonal antibody (PK136) or control mouse 
IgG2a was injected intraperitoneally (i.p.) on days −3, 2, and 8. 
B16F10 cells (5 × 105 cells) in 0.2 mL of PBS were injected subcu-
taneously into the right flanks of mice on day 0. The tumour vol-
ume was measured after dissection on day 18 after injection of 
melanoma cells. To evaluate the activity of resveratrol, mice were 
intravenously injected a total of 6 times, on days −2, 0, 2, 4, 6, and 
8. Asterisks indicate statistical significance by one-way ANOVA: 
*p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant (p > 0.05). 
RES, resveratrol; IL-2, interleukin-2; IFN-γ, interferon-gamma; 
NK cells, natural killer cells. (For figure see next page.)

























































































































































































































Resveratrol Activates NK Cells in vivo 103J Innate Immun 2021;13:94–106
DOI: 10.1159/000510315
bearing mouse models. Even in the presence of an activa-
tor, NK cell activity was significantly lower in the tumour-
bearing mouse than in the tumour-naïve group (Fig. 6b). 
However, after resveratrol treatment in the presence of 
the activator, NK cell activity increased by about 27.3% 
compared to treatment with the activator alone in the tu-
mour-bearing mouse (Fig. 6b). Finally, PBMCs were iso-
lated from whole blood and treated with resveratrol for 
24 h in the presence IL-2 and then stimulated by K562 
target cells (Fig.  6c). Intriguingly, compared with IL-
2-treated cells, we found that resveratrol significantly en-
hanced degranulation in CD56dimCD16+ human primary 
NK cells known for their cytolytic activity (Fig. 6c) [26]. 
Thus, these results indicate that resveratrol has potential 
to activate human primary NK cells and suggest that res-












































































Fig. 6. Ex vivo effects of resveratrol in human and mouse whole 
blood. a For the human NK cell activity assay, 1 mL of whole blood 
was incubated with or without the activator and resveratrol for 
24 h at 37°C. b For the mouse NK cell activity assay, 100 μL of 
whole blood was incubated with or without 30 μL activator and 
resveratrol for 24 h at 37°C (tumour-naïve or tumour-bearing 
mouse model, n = 8). The supernatant was collected, and the re-
leased IFN-γ was measured using the NK Vue kit. c CD107a ex-
pression of primary NK cells was measured by flow cytometry. 
PBMCs were treated with 20 μM resveratrol for 24 h in the presence 
of IL-2, followed by co-culture with K562 target cells at a 5:1 (E:T) 
ratio for 4 h (n= 5). Asterisks indicate statistical significance by 
Dunn’s multiple comparison test: *p < 0.05; **p < 0.01; ***p < 
0.001; ns, not significant (p > 0.05). IL-2, interleukin-2; IFN-γ, in-
terferon-gamma; RES, resveratrol.
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Discussion
Resveratrol is a natural compound and antioxidant 
found in peanuts, soy, hop, and various fruits, especially 
grapes and red wines [27, 28]. Resveratrol possesses vari-
ous biological activities, including anti-tumour, anti-vi-
ral, anti-inflammation, anti-fungal, and antibacterial ef-
fects [27, 29–32]. We have demonstrated that resveratrol 
increases the expression of activating receptors on NK 
cells (Fig. 3). Interestingly, we found that resveratrol + 
IL-2 significantly increase NKp30 more than IL-2 alone. 
Especially, NKp30a and NKp30b isoforms that have im-
mune-stimulatory roles were significantly increased by 
resveratrol more than IL-2 alone. One of the proposed 
approaches for tumour therapy is enhancing tumour sen-
sitivity to NK cell cytolysis by upregulating the NKp30 
ligand B7-H6 on tumour cells using stress inducers [33]. 
Moreover, preclinical approaches involve increasing tu-
mour sensitivity to NK cells by upregulating the expres-
sion of NKG2D ligands on cancer cells using HDAC in-
hibitors [34]. Enhancement of cell surface expression of 
NKG2D ligands and DR4/5 on various cancer cells by res-
veratrol increases TRAIL sensitivity and could facilitate 
NK cell-mediated killing of cancer cells [35, 36]. How-
ever, there are no reports that resveratrol also increases 
B7-H6 expression on cancer cells. If resveratrol did in-
duce the expression of B7-H6 on cancer cells, it would be 
a good candidate for an anti-cancer drug, acting as both 
an immune stimulator for NK cells and a stress inducer 
for cancer cells.
NK cells require IL-2 to proliferate, and resveratrol 
treatment without IL-2 did not affect IFN-γ secretion or 
NK cytotoxicity in vitro (Fig. 2). IL-2 is capable of activat-
ing NK cells and is used as an anti-cancer drug in immu-
notherapy [37]. According to a recent report, resveratrol 
has shown promising results in adjuvant therapy [27]. 
Resveratrol in combination with 5-fluoruracyl or cispla-
tin exhibited synergistic effects in the induction of apop-
tosis in cancer cells in vitro and in vivo [38, 39]. There-
fore, resveratrol can be expected to exert a greater effect 
in combination with IL-2.
Resveratrol shows a concentration-dependent bipha-
sic effect [40]. Low doses of resveratrol reportedly activate 
NK cells, while high doses reportedly promote cell apop-
tosis via the caspase signalling pathway [40]. In one study, 
NK cell killing activity was enhanced at low concentra-
tions of resveratrol ranging from 0.33 to 5.48 μM, with a 
maximum activity at 1.31 μM; however, NK cell killing 
activity was inhibited at higher concentrations of 21.92 
and 87.68 μM resveratrol [41]. In another study by Lu and 
Chen [42], 12.5 μM resveratrol induced the highest NK 
cell killing activity. In our study, resveratrol did not sig-
nificantly affect NK cell proliferation in vitro, but it did 
increase IFN-γ secretion in a dose-dependent manner up 
to a concentration of 20 μM. We also found that resvera-
trol increased IFN-γ secretion ex vivo at a concentration 
of 20 μM and did not affect survival when injected into 
mice at 0.5 mg/kg (data not shown).
Resveratrol is currently being sold as a dietary supple-
ment. Resveratrol is first detectable in plasma 15 min 
after oral administration, reaching its peak concentra-
tion after 30 min, and it is quickly metabolized in the 
intestine and liver into glucuronide and sulphate conju-
gates [43]. According to a study on the absorption of 
wine-related polyphenols, the highest serum level of to-
tal resveratrol (free and conjugated) was recorded after 
consumption of 25-mg trans-resveratrol per 70 kg body 
weight in 3 different matrices (wine, grape juice, and 
vegetable juice) [44]. Free trans-resveratrol accounted 
for 1.7–1.9% of the peak total serum concentration. This 
is considerably lower than the concentrations tested in 
vitro showing beneficial effects. Moreover, resveratrol is 
rapidly metabolized in the intestine by phase II enzymes, 
so it is very difficult to reach pharmacologically effective 
systemic plasma concentrations, which might signifi-
cantly restrict the bioavailability of resveratrol [45, 46]. 
Our data showed that IFN-γ secretion increased upon 
treatment with intact resveratrol but not with its me-
tabolites (Fig.  4). Accordingly, resveratrol would be 
more effective when administered by injection rather 
than by diet.
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